COMMUNIQUÉS West-GlobeNewswire

New Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care Model
26/10/2026
More than 70% of members in the study reported symptom improvement, with the greatest gains among those receiving both personalized coaching and menopause-trained provider care NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE [...]
Seek Labs Expands Oncology Research for Sequence Ablation Therapeutics with Up to $3 Million in Foundation Support
26/10/2026
Two2Ten Foundation supports the continued development of Seek Labs’ Sequence Ablation Therapeutics (SAT) platform into oncology, honoring the memory of Travis Snyder SALT LAKE CITY, Oct. 26, 2026 (GLOBE NEWSWIRE) -- [...]
Erdem Hospital Wins Two GIGI Awards for World Cup Connected TV Campaign
26/10/2026
Erdem Hospital’s international advertising campaign used live 2026 FIFA World Cup match data to deliver real-time, local-language messages across key European markets, earning two awards at the 16th GIGI Awards ISTANBUL [...]
Novo Nordisk A/S - share repurchase programme
26/10/2026
Bagsværd, Denmark, 26 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR [...]
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia
26/10/2026
- Obtaining Orphan designation from the European Commission reflects Solid’s commitment to the global development of SGT-212 for individuals living with Friedreich’s ataxia - - SGT-212 is a first-in-class dual route FA [...]
Amwell® to report third quarter 2026 operating results
26/10/2026
BOSTON, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL a leading provider of technology-enabled care, will report third quarter 2026 operating results after stock market trading hours on Tuesday, November 3. [...]
Affordable Pet Labs Launches Nationwide Validation Study of an At-Home Heartworm Test, and Invites Dog Owners in 52 Cities to Help
26/10/2026
More than 1,500 dogs will receive a complete heartworm test from a visiting APL technician at no cost. If the new method meets the current gold standard, APL plans to bring it to pet parents nationwide, direct to [...]
Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity
26/10/2026
New wholly owned subsidiary, led by Adrian Jones, to expand the Company's network of clinics and pharmacies across Australia VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: [...]
BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
26/10/2026
CARSON CITY, Nev., Oct. 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases [...]
Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline
26/10/2026
Amy Rock, Ph.D., appointed Chief Regulatory and Quality Officer, bringing extensive experience in global regulatory strategy, clinical development, and with approvals of novel immunotherapies Dae Gon Ha, Ph.D., [...]
TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
26/10/2026
COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with [...]
Novastra Therapeutics Reports Encouraging First Clinical Data for Its Novel XIRT™/OAP Cancer Immune Therapy at ESMO Congress 2026
26/10/2026
Initial data from an investigator-initiated Phase 1 study provide early proof of concept for systematic immune reprogramming therapy (XIRT™) XIRT is built on Novastra’s proprietary OmniAntigen™ Platform (OAP) designed [...]
Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature
26/10/2026
Study combines AI-guided literature investigation with gene-expression analysis to identify a four-gene signature for Sapu003 development Source: Oncotelic Therapeutics, Inc. AGOURA HILLS, Calif., Oct. 26, 2026 (GLOBE [...]
Seismic Therapeutic to Participate in Upcoming Investor Conferences
26/10/2026
WATERTOWN, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Seismic Therapeutic, Inc. today announced that company management will participate in the following investor conferences: Stifel 2026 Healthcare Conference Date: [...]
Certara to Report Third Quarter 2026 Financial Results on November 5th, 2026
26/10/2026
RADNOR, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2026 [...]
Stryker completes acquisition of ZuriMED to enhance its shoulder offering
26/10/2026
Portage, Michigan, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Stryker has completed its acquisition of ZuriMED, adding the FiberLocker System to its Sports Medicine portfolio The acquisition adds a commercialized rotator cuff [...]
Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World’s First CGM System with No On-body Component
26/10/2026
First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics’ innovation roadmap, with potential launch in 2028 Built on the proven sensing technology behind [...]
Major shareholder announcement
26/10/2026
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis has received a major shareholder notification from BlackRock, Inc. regarding its holdings in Novonesis. As of October 21, 2026, BlackRock, Inc.’s [...]
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
26/10/2026
Single-agent NXP200 was administered to 27 patients with recurrent or progressive gliomas (20 with high-grade and 7 with low-grade). The objective response rate (ORR) based on Response Assessment in Neuro-Oncology [...]

Pages